Equity Profile

ASND

Ascendis Pharma A/S

Health CareBiotechnology$16.2B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare diseases and endocrine disorders. With a market cap of $16 billion, it operates in the health care sector, which is increasingly important as demand for specialized treatments grows.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

In Q1 2026, Ascendis Pharma reported an impressive EPS of $11.46, significantly beating expectations. The stock reacted positively, increasing by 4.34% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials for its lead product candidates.
Commitment to maintaining strong R&D investment.
Plans to expand market access for existing therapies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as analysts await clarity on revenue and future guidance. The stock's recent performance has created both optimism and caution among investors.

Bull Case

If the company continues to show strong EPS growth and positive developments in its product pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet revenue expectations or shows signs of increased R&D costs without corresponding results, the stock may decline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026?

Given the significant surprise in the previous quarter, investors will be keen to see if this trend continues or if it was an anomaly.

How much is the company investing in R&D this quarter?

R&D spending will indicate the company's commitment to future growth and innovation, which is critical for its long-term success.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Ascendis to sustain its recent earnings momentum, given its strong pipeline and R&D focus.

Supporting Evidence

The company's recent EPS surprise indicates strong operational efficiency.

Options pricing suggests a significant move, indicating investor uncertainty that could lead to volatility.

Historical performance shows that the stock has reacted positively to earnings beats.

Key Risk

If R&D spending significantly exceeds expectations without clear results, it could undermine investor confidence.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether the company can sustain its recent earnings momentum and effectively invest in future growth.

Bull Confirmed If

An EPS of $12 or higher would confirm strong profitability and growth potential.

Bear Confirmed If

An EPS below $5 would raise concerns about the company's ability to manage costs and generate revenue.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis beats expectations, history suggests the stock could rise by around 4.71%, confirming a bullish outlook.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, as investors weigh the implications of management commentary.

Miss

If the company misses expectations, history suggests a potential decline of around 1.60%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress for lead product candidates.
2Details on revenue expectations for the upcoming quarters.
3Insights into R&D spending and its impact on future earnings.
4Management's outlook on market conditions and competitive landscape.
5Any new partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

In Q1 2026, Ascendis Pharma reported an impressive EPS of $11.46, significantly beating expectations. The stock reacted positively, increasing by 4.34% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials for its lead product candidates.
Commitment to maintaining strong R&D investment.
Plans to expand market access for existing therapies.

Expectations

Wall Street Expectations

Overall, expectations are mixed as analysts await clarity on revenue and future guidance. The stock's recent performance has created both optimism and caution among investors.

Bull Case

If the company continues to show strong EPS growth and positive developments in its product pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet revenue expectations or shows signs of increased R&D costs without corresponding results, the stock may decline.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2 2026?

Given the significant surprise in the previous quarter, investors will be keen to see if this trend continues or if it was an anomaly.

How much is the company investing in R&D this quarter?

R&D spending will indicate the company's commitment to future growth and innovation, which is critical for its long-term success.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential for Ascendis to sustain its recent earnings momentum, given its strong pipeline and R&D focus.

Supporting Evidence

The company's recent EPS surprise indicates strong operational efficiency.

Options pricing suggests a significant move, indicating investor uncertainty that could lead to volatility.

Historical performance shows that the stock has reacted positively to earnings beats.

Key Risk

If R&D spending significantly exceeds expectations without clear results, it could undermine investor confidence.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether the company can sustain its recent earnings momentum and effectively invest in future growth.

Bull Confirmed If

An EPS of $12 or higher would confirm strong profitability and growth potential.

Bear Confirmed If

An EPS below $5 would raise concerns about the company's ability to manage costs and generate revenue.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis beats expectations, history suggests the stock could rise by around 4.71%, confirming a bullish outlook.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, as investors weigh the implications of management commentary.

Miss

If the company misses expectations, history suggests a potential decline of around 1.60%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress for lead product candidates.
2Details on revenue expectations for the upcoming quarters.
3Insights into R&D spending and its impact on future earnings.
4Management's outlook on market conditions and competitive landscape.
5Any new partnerships or collaborations that could enhance growth.